Eligibility Details:
Inclusion Criteria:
- Male and female subjects 18 to 75 years of age inclusive
- BMI 18 -35 kg/m2
- If female, you are nonpregnant, non-lactating and willing to utilize approved methods
of birth control.
Exclusion Criteria:
- Subjects who have mild or moderate hepatic impairment according to Child-Pugh
classification system at Screening (except normal healthy matches)
- Subjects who have a known clinically significant (CS) hypersensitivity to MT-7117 or
related compounds, including melatonin.
- Subjects who have previously participated in a study involving MT-7117 or taken any
other investigational drug within 30 days or 5 half-lives prior to the first dose of
IMP, whichever is longer.
- Subjects who have a CS or unstable neurological, renal, cardiovascular,
gastrointestinal, pulmonary, or hematologic disease for 14 days prior to enrollment.
- Subjects who have used any prescription or over-the-counter (OTC) medication within 14
days prior to first dose of IMP, except for occasional use of acetaminophen (< 1 g/day
for normal hepatic subjects, and < 2 g/day for hepatically impaired subjects) or any
other medication approved by the sponsor (a case-by-case basis). For hepatic impaired
subjects, prescribed medication or OTC may be permitted by the Investigator and
sponsor on a case-by-case basis.